文献速递甲状腺疾病

甲状腺癌幸存者术后12个月持续存在症状与健康相关生活质量缺陷

Thyroid Cancer Survivors Experience Persistent Symptoms and Health-Related Quality-of-Life Deficits 12 Months Following Surgery.
PubMed 文献 · Thyroid · 2025-07-10

这项前瞻性纵向队列研究纳入111例新诊断甲状腺癌患者,术后及3、6、12个月重复评估生活质量。诊断一年后SF-12躯体与心理评分仍低于常模,声音与瘢痕症状改善,但神经肌肉、感觉症状及体重增加相关困扰加重,恐惧复发持续存在。

要点

  • 诊断后超过12个月,SF-12躯体评分均值39.4、心理评分均值46.7,均低于常模50。
  • 甲状腺癌生活质量调查显示声音与瘢痕症状改善(各p<0.01),神经肌肉(p<0.01)、感觉症状(p=0.01)及体重增加(p=0.04)相关困扰加重。
  • 恐惧癌症复发常见且随时间持续存在。

核心结论

  • 诊断一年后甲状腺癌幸存者仍存在持续的健康相关生活质量缺陷,且部分症状随时间加重。
  • 作者认为临床医生在随访中应专门询问可能影响生活质量的持续症状,并需要针对持续生活质量缺陷者的支持性照护干预。

研究设计与样本

  • 前瞻性纵向队列研究,从混合都市与区域卫生区(公立与私立)招募新诊断甲状腺癌患者,排除低风险甲状腺微小乳头状癌和未分化甲状腺癌。
  • 2021年1月至2023年6月共111例患者在至少一个时间点完成问卷,应答率59%。
  • 患者于术后及3、6、12个月完成SF-12、EORTC-QLQ-C30、甲状腺癌生活质量(ThyCaQoL)调查、City of Hope-甲状腺版及幸存者担忧评估问卷。

主要发现

  • 女性占72%,平均年龄55岁,都市居民56%,私人保险56%,美国甲状腺协会低风险分化型甲状腺癌55%。
  • 治疗包括全甲状腺切除49%、两阶段甲状腺切除24%、腺叶切除25%、主动监测2%;58%接受放射性碘消融。
  • 研究结束时82%甲状腺功能正常,92%无病。
  • 所有时间点SF-12躯体成分评分与心理成分评分均低于常模人群值(>12个月:躯体评分均值39.4,心理评分均值46.7,常模=50)。
  • 心理成分评分在诊断后第一年显示较一致改善(总体p=0.03);ThyCaQoL显示声音与瘢痕症状改善(各p<0.01),但神经肌肉(p<0.01)、感觉症状(p=0.01)及体重增加(p=0.04)相关困扰在研究期间加重,恐惧癌症复发常见且持续存在。

临床怎么用

  • 作者认为,作为随访照护的一部分,临床医生应专门询问可能影响生活质量的持续症状。
  • 作者指出,需要为存在持续健康相关生活质量缺陷者提供支持性照护干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid cancer survivors may experience significant health-related quality-of-life (HRQoL) detriments. Currently available HRQoL survey tools, used in isolation, can be insensitive to change over time and may incompletely assess thyroid cancer-specific symptoms and fear of cancer recurrence. This study aimed to measure the trajectory of HRQoL changes in thyroid cancer survivors using repeated measures, comparing commonly used surveys, over the first 12-18 months following diagnosis. Methods: A prospective longitudinal cohort study recruited all patients with newly diagnosed thyroid cancer (excluding low-risk papillary thyroid microcarcinoma and anaplastic thyroid cancer) from a mixed metropolitan and regional health district (public and private). Patients were invited to complete Short Form-12 (SF-12), EORTC-QLQ-C30, Thyroid Cancer Quality of Life (ThyCaQoL) Survey, City of Hope-Thyroid Version, and Assessment of Survivor Concerns surveys postoperatively, and at 3, 6, and 12 months. Responses were assessed for changes over time, and multivariable analysis was used to identify variables associated with outcomes at follow-up. Results: Between January 2021 and June 2023, 111 patients completed surveys at a minimum of one time point (response rate 59%). Most were female (72%), mean age 55 years, 56% metropolitan, 56% privately insured, 55% American Thyroid Association low-risk differentiated thyroid cancer. Treatment included surgery (total thyroidectomy 49%, two-stage thyroidectomy 24%, lobectomy 25%, active surveillance 2%); 58% received radioactive iodine ablation. At the completion of the study, 82% were euthyroid and 92% disease-free. At all time points, SF-12 physical and mental component scores (PCS and MCS), remained below normative population values (>12 months; mean PCS = 39.4, mean MCS = 46.7, normative = 50). MCS showed more consistent improvement over the first year following thyroid cancer diagnosis (global p = 0.03). ThyCaQoL surveys identified improvement in voice and scar symptoms (p < 0.01 each), but distress regarding neuromuscular (p < 0.01), sensory symptoms (p = 0.01), and weight gain (p = 0.04) worsened over the course of the study. Fear of cancer recurrence was common and persisted over time. Conclusion: A year after diagnosis, thyroid cancer survivors have persisting HRQoL deficits with some symptoms worsening over time. As part of follow-up care, clinicians should specifically inquire about persistent symptoms that could affect HRQoL. Supportive care interventions for those with persistent HRQoL deficits are required.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. O'Neill CJ, Rowe CW, Morris-Baguley H, et al. Thyroid Cancer Survivors Experience Persistent Symptoms and Health-Related Quality-of-Life Deficits 12 Months Following Surgery. Thyroid. 2025. PMID: 40637758. doi:10.1089/thy.2025.0149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。